Perrigo (PRGO) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viridian Therapeutics (VRDN) has outperformed Perrigo (PRGO) over the past year, losing 14.1% versus a loss of 33.0%. Over five years, VRDN leads with a +7.4% price change compared with -67.6% for PRGO. Viridian Therapeutics is the larger company by market cap ($2.10 billion vs $2.10 billion), about 1.0 times the size.
Perrigo pays a dividend yielding 7.65%, while Viridian Therapeutics does not currently pay one. Perrigo converts more of its revenue into profit, with a net margin of -33.5% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | VRDN |
|---|---|---|
| Share price | $15.16 | $18.57 |
| Market cap | $2.10B | $2.10B |
| 1-day change | +4.55% | +1.25% |
| YTD return | +4.17% | -41.07% |
| 1-year return | -33.03% | -14.14% |
| 5-year return | -67.58% | +7.44% |
| Forward P/E | 6.32 | — |
| EPS (TTM) | $-12.28 | $-3.39 |
| Dividend yield | 7.65% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| Revenue (latest FY) | $4.25B | $70.85M |
| Revenue growth (YoY) | -2.75% | +23359.93% |
| Net income (latest FY) | $-1.43B | $-342.60M |
| Gross margin | 35.14% | — |
| Operating margin | -26.39% | -512.91% |
| Net margin | -33.51% | -483.57% |
| 52-week high | $22.02 | $34.29 |
| 52-week low | $9.23 | $13.18 |
| Distance from 52-week high | -31.15% | -45.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +8.84% | +97.90% |
| Average volume | 2.80M | 1.71M |
| Shares outstanding | 138.37M | 113.29M |
| Employees | 8,100 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRDN has outperformed PRGO by 18.9 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.65% vs 0.00%).
- Perrigo is more profitable, keeping -33.5 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs -2.75%).
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
PRGO vs VRDN FAQ
Which is bigger, Perrigo or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $2.10B compared with $2.10B for Perrigo (PRGO).
Which stock has performed better over the past year, PRGO or VRDN?
VRDN returned -14.14% over the past 12 months, compared with -33.03% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or Viridian Therapeutics?
Perrigo pays a dividend yielding 7.65%, while Viridian Therapeutics does not currently pay a regular dividend.
Are Perrigo and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.